Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate. [PDF]
Brown G +8 more
europepmc +1 more source
Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer. [PDF]
Nakagami Y +7 more
europepmc +1 more source
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. [PDF]
Attard G +22 more
europepmc +1 more source
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]
Maguire WF +21 more
europepmc +1 more source
Synthesis of the Abiraterone Derivatives 5α- and 5β-Δ<sup>1</sup>-Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate. [PDF]
Hayama N +7 more
europepmc +1 more source
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. [PDF]
Castro E +7 more
europepmc +1 more source
Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients. [PDF]
Chiong E +15 more
europepmc +1 more source
Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC. [PDF]
Castro E +7 more
europepmc +1 more source
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. [PDF]
Shaver AL +6 more
europepmc +1 more source
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate. [PDF]
Shi Y +13 more
europepmc +1 more source

